Woman Man | 18 years and more
- | Country :
- France
- | organs :
- Sein
- Métastases cérébrales
- | Specialty :
- Chimiothérapie
Extract
A single arm, open-label trial assessing the effect of capecitabine (Xeloda®) on progression-free survival rate at four months in breast cancer patients with CNS progression after whole brain radiotherapy.
Scientific Abstract
en cours d'intégration;